Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance

This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone. During these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results. No experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.

NCT Number	NCT07636148
Lead Sponsor	Mark C Burgmans, MD PhD Collaborators: European Commission, Philips Medical Systems, Philips Electronics Nederland BV, Philips France Commercial, Philips GmbH Innovate Technologies, Quantum Surgical, IGEA, Hospices Civils de Lyon, Assistance Publique - Hôpitaux de Paris, EIBIR - European Institute for biomedical imaging research, Cardiovascular and Interventional Radiological Society of Europe, Klinikum der Universität zu Köln, Institut für Klinische Chemie
Conditions	Liver Cancer (Primary and Metastatic), Lung Cancer (Diagnosis), Bone Cancer Metastatic, Bone Cancer Tumor, Kidney Tumors, Renal Cancer, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (Kidney Cancer) +5 more
Enrollment	2,000 participants
Start Date	2026-07-01
Primary Completion	2030-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-09